Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET
Company Participants
Jacqueline Shea - President and Chief Executive Officer
Conference Call Participants
Li Chen - H.C. Wainwright
Li Chen
Good afternoon, everyone, and welcome to H.C. Wainwright 25th Annual Global Investment Conference. My name is Li Chen, and I'm H.C. Wainwright Equity Research Associate.
I'd like now to welcome our next speaker, Dr. Jacqueline Shea, President and CEO of Inovio Pharma, a biotech company focused on developing and commercializing DNA medicines. Please go ahead.
Jacqueline Shea
Thank you. It's a pleasure to talk with you this afternoon. I'm Jackie Shea. I'm the CEO of Inovio Pharmaceuticals.
Before I move into the presentation, I'd like to provide the standard disclaimer that I'll be making forward-looking statements during this presentation. And I'd like to refer to you to our file 10-K and most recent 10-Q filed on June 30th for further details.
So, to provide a quick overview of Inovio, we are a biotech company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases. Our platform aims to optimize the design and delivery of our DNA medicines with the aim of creating therapies and vaccines that teach the body to manufacture its own disease fighting tools.
We have approximately $194 million in cash at the end of the second quarter of this year, with an expected cash runway into the third quarter of 2025. We've been building a really strong team with experienced and expertise in bringing innovative new products to market to benefit patients. And over the past year, I've added new leaders across regulatory of medical, R&D, and a new Chief Medical Officer. We're headquartered just outside of Philadelphia and we have R&D facilities and manufacturing facilities in
- Read more current INO analysis and news
- View all earnings call transcripts